A prespecified overall survival analysis of the phase 3 ZUMA-7 trial found that axicabtagene ciloleucel (axi-cel) led to better outcomes vs the historical standard of care for relapsed or refractory large B-cell lymphoma (R/R LBCL).
Axicabtagene ciloleucel (axi-cel; Yescarta) showed a statistically significant overall survival (OS) improvement compared with standard-of-care (SOC) initial treatment for relapsed or refractory large B-cell lymphoma (R/R LBCL) in the landmark ZUMA-7 study, Kite Pharma today announced in a press release.1
The phase 3 ZUMA-7 trial is a randomized, open-label, multicenter, international study considered to be the largest phase 3 study of any chimeric antigen receptor (CAR) T-cell therapy, according to the release. The trial has also shown axi-cel to produce an event-free survival (EFS) improvement over historical SOC therapy—the main end point in the trial.
In the prespecified OS analysis, the axi-cel cohort showed a 2.5-fold increase in patients who were alive, did not experience disease progression, and did not need additional cancer treatment at 2 years. The median EFS in the axi-cel cohort was 8.3 months compared with 2 months in the SOC group.
Additionally, more patients responded to axi-cel (83%) vs SOC (50%), and more patients achieved complete response with axi-cel (65%) vs SOC (32%). More than half of patients randomized to the SOC group later received axi-cel off study.
The full results of the analysis will be presented at a meeting later in the year.
Historically, the SOC for R/R LBCL that occurs within 12 months of first-line therapy includes a platinum-based salvage combination chemoimmunotherapy regimen, followed by high-dose therapy, then autologous stem cell transplant in patients whose disease responds to salvage chemotherapy.
The ZUMA-7 study randomized 359 patients at 77 centers 1:1 to receive either a single dose of axi-cel or SOC therapy for R/R LBCL.2 OS, defined as the time from randomization to all-cause mortality, was prespecified as a clinically important secondary end point that would be analyzed either after 210 deaths or no later than 5 years after the first patient was randomized.
The new findings make axi-cel the first and only treatment in almost 3 decades to demonstrate a statistically significant OS improvement vs SOC therapy in R/R LBCL, according to the release. The news release also noted that in the ZUMA-7 study, patients in the axi-cel arm did not receive bridging chemotherapy prior to CAR T-cell therapy that could affect the results, and the study did not identify any new safety signals with axi-cel.
The trial was conducted under a Special Protocol Assessment, meaning the FDA agreed with the clinical end points and prespecified statistical analyses in the study. Data from ZUMA-7 were also the basis of axi-cel’s FDA approval as a second-line therapy for LBCL in 2022.3
References
1. Kite’s Yescarta CAR T-cell therapy demonstrates a statistically significant improvement in overall survival for initial treatment of relapsed/refractory large B-cell lymphoma. News release. Kite. March 21, 2023. Accessed March 21, 2023. https://www.kitepharma.com/news/press-releases/2023/3/kites-yescarta-car-t-cell-therapy-demonstrates-a-statistically-significant-improvement-in-overall-survival-for-initial-treatment-of-relapsedrefract
2. Efficacy of axicabtagene ciloleucel compared to standard of care therapy in subjects with relapsed/refractory diffuse large B cell lymphoma (ZUMA-7). ClinicalTrials.gov. Updated February 3, 2023. Accessed March 21, 2023. https://clinicaltrials.gov/ct2/show/NCT03391466
3. FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma. News release. FDA. April 1, 2022. Accessed March 21, 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-axicabtagene-ciloleucel-second-line-treatment-large-b-cell-lymphoma
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Reveals Link Between Ovarian Cancer, Subsequent Dry Eye Disease Incidence
May 13th 2024Patients diagnosed with ovarian cancer (OC), particularly those older than 60 years or with a disease duration exceeding 5 years, had a higher incidence of subsequent dry eye disease (DED), suggesting a potential correlation between OC and DED.
Read More
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More